Compare Abeona Therapeutics Inc (ABEO) vs US Bancorp (USB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs US Bancorp — how do they compare? Abeona Therapeutics Inc trades at $6.72 (market cap $373.32M), while US Bancorp trades at $61.14 (market cap $97.97B). The key difference: US Bancorp is far larger — about 262.4× Abeona Therapeutics Inc's market cap, and US Bancorp pays a 3.31% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | USB | |
|---|---|---|
Market Cap | $373.32M | $97.97B |
Sector | Health | Financials |
52-Week High | $7.23 | $62.89 |
52-Week Low | $4.17 | $43.94 |
Enterprise Value | $228.22M | — |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
U.S. Bancorp (USB) trades at $62.89, up 1.88% on the day, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. The company reported 2025 net income of $7.57 billion, with a net margin of 27.04%, and maintains a solid dividend history, including a recent $0.52 per share payout. Analyst consensus is mixed but leans positive, with a price target of $66.64.
USB's outlook is supported by robust profitability and strategic partnerships, but risks include interest rate sensitivity and competitive pressures. The stock offers value with a P/E of 13.17, though investors should monitor net cash flow trends and economic conditions affecting banking sector performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
